A Study to Evaluate MEDI5752 in Subjects with Advanced Solid Tumors

Exclusion Criteria

• 1. Involvement in the planning and/or conduct of the study (applies to both MedImmune staff and/or staff at the study site)
• 2. Concurrent enrollment in another clinical study, unless it is an observational clinical study or the follow-up period of an interventional study
• 3. For subjects who have received prior anti-PD-1, anti-PD-L1, or anti-CTLA-4:
• a. Subjects must not have received anti-PD-1, anti-PD-L1, anti-CTLA-4 or any other immunotherapy or immune-oncology (IO) agent within 21 days of commencing treatment with investigational product.
• b. Subject must not have experienced a toxicity that led to permanent discontinuation of prior immunotherapy.
• c. All AEs while receiving prior immunotherapy must have completely resolved or resolved to Grade 1 prior to screening for this study.
• 4. Current or prior use of immunosuppressive medication within 14 days before the first dose of investigational product is excluded.
• 5. Receipt of live attenuated vaccine within 30 days prior to the first dose of investigational product.
• 6. Active or prior documented autoimmune or inflammatory disorders
• 7. History of active primary immunodeficiency:
• 8. History of organ transplant
• 9. Known allergy or reaction to any component of the planned study treatment.
• 10. Untreated CNS metastatic disease, leptomeningeal disease, or cord compression
• 11. Unresolved toxicities from prior anticancer therapy, defined as having not resolved to NCI CTCAE v4.03 Grade 0 or 1, or to levels dictated in the inclusion/exclusion criteria
• 12. Major surgical procedure (as defined by the investigator) within 28 days prior to the first dose of Investigational Product or still recovering from prior surgery
• 13. Female subjects who are pregnant or breastfeeding, as well as male or female subjects of reproductive potential who are not willing to employ one highly effective method of birth control
• 14. Uncontrolled intercurrent illness, that would limit compliance with study requirement, substantially increase risk of incurring AEs or compromise the ability of the subject to give written informed consent.
• 15. Any condition that, in the opinion of the investigator, would interfere with evaluation of the investigational product or interpretation of the subject’s safety or study results
• 16. Judgment by the investigator that the subject is unsuitable to participate in the study and the subject is unlikely to comply with study procedures, restrictions, and requirements.